A Phase 1b/2a Open-Label, Multi-Center Study to Assess the Safety, Efficacy and Pharmacokinetics of Intrapatient Dose-Adjusted Brequinar and Inhibition of Dihydroorotate Dehydrogenase (DHODH) in Adult Subjects with Acute Myelogenous Leukemia (AML).
Brequinar, Dihydroorotate Dehydrogenase
The goal of this clinical research study is to learn about the safety and tolerability of brequinar when given to patients with acute myelogenous leukemia (AML). Researchers also want to learn if brequinar can help decrease the levels of an enzyme called dihydroorotate dehydrogenase (DHODH). DHODH stops blood cells in the bone marrow from growing into mature white blood cells (cells that can help fight infection) and platelets (cells that help blood to clot). Lowering DHODH levels in AML patients may help cells in the bone marrow to grow into mature cells to help the body fight cancer.
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: Brequinar, Dihydroorotate Dehydrogenase
Treatment Location: Both at MD Anderson & Other Sites
Sponsor: Clear Creek Bio
IRB Review and Approval Date: 11/27/2018
Recruitment Status: Open
Projected Accrual: 27
Information and next steps
Malignant neoplasms stated as primary lymphoid haematopoietic
For general questions about clinical trials: